Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis
Marco Merli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Hamid Hasson(Vita-Salute San Raffaele University), Emanuela Messina(Vita-Salute San Raffaele University), Antonella Castagna(Vita-Salute San Raffaele University), Laura Galli(Vita-Salute San Raffaele University), Antonio D’Avolio(Ospedale Amedeo di Savoia), Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), Stefano Bonora(Ospedale Amedeo di Savoia), Adriano Lazzarin(Vita-Salute San Raffaele University), Alessandra Ariaudo(University of Turin), Letizia Marinaro(University of Turin)
Cited by 8
Related Papers
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
|PLoS Medicine|2013|362
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
|New England Journal of Medicine|2022|312